Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 35
Filter
1.
Int J Infect Dis ; 25: 79-81, 2014 Aug.
Article in English | MEDLINE | ID: mdl-24857802

ABSTRACT

OBJECTIVES: To evaluate the emergence of New Delhi metallo-ß-lactamase 1 (NDM-1)-producing Enterobacteriaceae isolates in Brazil. METHODS: From April to October 2013, following the detection of the first NDM-1-producing isolate, a surveillance study was performed for the detection of blaNDM-1 among Enterobacteriaceae isolates with reduced susceptibility to carbapenems in 17 hospitals of Porto Alegre, Brazil. Real-time PCR was used to determine the presence of carbapenemase genes, which were further sequenced. Clonal relatedness was assessed by pulsed-field gel electrophoresis (PFGE). RESULTS: A total of 1134 isolates were evaluated. blaNDM-1 was detected in 11 (0.97%) isolates: nine Enterobacter cloacae complex (eight belonging to a single clone recovered from two distinct hospitals and the other strain from a third hospital) and two Morganella morganii (belonging to a single clone recovered from one hospital). Most isolates presented high-level resistance to carbapenems. CONCLUSIONS: NDM-1-producing Enterobacteriaceae have emerged rapidly in the hospitals of the Brazilian city where they were first detected. The emergence of NDM-1 in Brazil is of great concern, since it is a severe threat to antimicrobial therapy against Enterobacteriaceae in this country.


Subject(s)
Communicable Diseases, Emerging , Enterobacteriaceae Infections/epidemiology , Enterobacteriaceae Infections/microbiology , Enterobacteriaceae/genetics , beta-Lactamases/genetics , Anti-Bacterial Agents/pharmacology , Brazil/epidemiology , Cross Infection , Enterobacteriaceae/drug effects , Enterobacteriaceae/isolation & purification , Humans , Microbial Sensitivity Tests , beta-Lactamases/biosynthesis
3.
J Pediatr (Rio J) ; 85(6): 531-5, 2009.
Article in English, Portuguese | MEDLINE | ID: mdl-20016870

ABSTRACT

OBJECTIVE: To compare the use of intravenous vs. oral antibiotic therapy. METHODS: All febrile neutropenic patients younger than 18 years old with low risk of complications and receiving chemotherapy were selected. The study was conducted from 2002 to 2005 at the Pediatric Oncology Unit of Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil. Patients were divided into group A and group B and were randomly assigned to receive oral or intravenous therapy. The empirical antimicrobial treatment used for group A consisted in oral ciprofloxacin plus amoxicillin-clavulanate and intravenous placebo, and group B received cefepime and oral placebo. RESULTS: A total of 91 consecutive episodes of febrile neutropenia in 58 children were included in the study. For patients of group A, treatment failure rate was 51.2%; the mean length of hospital stay was 8 days (range 2-10 days). For patients treated with intravenous antibiotic therapy, treatment failure rate was 45.8%; the mean length of hospital stay was 7 days (range 3-10 days). CONCLUSION: There was no difference in the outcome in oral vs. intravenous therapy. There is need of larger randomized trials before oral empirical therapy administered to this population should be considered the new standard of treatment.


Subject(s)
Amoxicillin-Potassium Clavulanate Combination/therapeutic use , Anti-Bacterial Agents/therapeutic use , Ciprofloxacin/therapeutic use , Neoplasms/drug therapy , Neutropenia/drug therapy , Administration, Oral , Child , Child, Preschool , Epidemiologic Methods , Female , Humans , Injections, Intravenous , Length of Stay , Male , Neutropenia/mortality
4.
J. pediatr. (Rio J.) ; 85(6): 531-535, nov.-dez. 2009. tab
Article in Portuguese | LILACS | ID: lil-536183

ABSTRACT

OBJETIVO: Comparar o uso de antibioticoterapia endovenosa versus oral. MÉTODOS: Foram selecionadas todas as crianças e adolescentes neutropênicos com idade inferior a 18 anos classificados como baixo risco para complicações e recebendo quimioterapia. O estudo ocorreu entre 2002 e 2005 na Unidade de Oncologia Pediátrica, Hospital de Clínicas de Porto Alegre, Porto Alegre (RS). Os pacientes, divididos em grupo A e grupo B, eram randomizados para receber terapia oral ou endovenosa. O tratamento utilizado para o grupo A foi ciprofloxacina e amoxicilina/clavulanato via oral e placebo endovenoso e, para o grupo B, cefepime e placebo oral. RESULTADOS: Foram selecionados 91 episódios consecutivos de neutropenia febril em 58 crianças. Para os pacientes do grupo A, a taxa de falência foi de 51,2 por cento e a média de tempo de hospitalização foi de 8 dias (variação de 2-10). Para os pacientes tratados com antibioticoterapia endovenosa, a taxa de falência foi de 45,8 por cento e a média de tempo de hospitalização foi de 7 dias (variação de 3-10). CONCLUSÃO: Neste estudo não houve diferenças entre a antibioticoterapia oral versus a terapia endovenosa. Estudos randomizados com maior número de pacientes são necessários antes de padronizar a terapêutica oral como tratamento para esta população de pacientes.


OBJECTIVE: To compare the use of intravenous vs. oral antibiotic therapy. METHODS: All febrile neutropenic patients younger than 18 years old with low risk of complications and receiving chemotherapy were selected. The study was conducted from 2002 to 2005 at the Pediatric Oncology Unit of Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil. Patients were divided into group A and group B and were randomly assigned to receive oral or intravenous therapy. The empirical antimicrobial treatment used for group A consisted in oral ciprofloxacin plus amoxicillin-clavulanate and intravenous placebo, and group B received cefepime and oral placebo. RESULTS: A total of 91 consecutive episodes of febrile neutropenia in 58 children were included in the study. For patients of group A, treatment failure rate was 51.2 percent; the mean length of hospital stay was 8 days (range 2-10 days). For patients treated with intravenous antibiotic therapy, treatment failure rate was 45.8 percent; the mean length of hospital stay was 7 days (range 3-10 days). CONCLUSION: There was no difference in the outcome in oral vs. intravenous therapy. There is need of larger randomized trials before oral empirical therapy administered to this population should be considered the new standard of treatment.


Subject(s)
Child , Child, Preschool , Female , Humans , Male , Amoxicillin-Potassium Clavulanate Combination/therapeutic use , Anti-Bacterial Agents/therapeutic use , Ciprofloxacin/therapeutic use , Neoplasms/drug therapy , Neutropenia/drug therapy , Administration, Oral , Epidemiologic Methods , Injections, Intravenous , Length of Stay , Neutropenia/mortality
5.
Arq Gastroenterol ; 44(2): 128-32, 2007.
Article in English | MEDLINE | ID: mdl-17962857

ABSTRACT

BACKGROUND: Infections after liver transplantations are the most important cause of morbi-mortality. In this study, we assessed the main characteristics of these infections in a southern Brazilian university hospital. METHODS: We conducted a retrospective cohort with 55 patients who underwent orthotopic liver transplantation between 1996 and 2000 in the "Hospital de Clínicas de Porto Alegre", Porto Alegre, RS, Brazil, to characterize the infections that occurred in the group. RESULTS: One or more infections (average 2.10) were diagnosed in 47 patients, especially during the first month after transplantation. The most common were bacteremia, intra-abdominal infections and pneumonia, predominantly with bacteria, especially Staphylococcus sp (and particularly S. aureus) and E. coli. The mortality rate attributed to infections was high: 17 cases of all deaths (total 27 deaths). Significant risk factors for infections included reoperation, diabetes, biliary stenosis and higher Child-Pugh scores. CONCLUSION: Infections remain a severe threat in liver transplant patients, and special efforts should be made to prevent and manage them correctly.


Subject(s)
Liver Transplantation/adverse effects , Opportunistic Infections/mortality , Adolescent , Adult , Aged , Brazil/epidemiology , Epidemiologic Methods , Female , Hospitals, University/statistics & numerical data , Humans , Immunocompromised Host , Liver Transplantation/mortality , Male , Middle Aged
6.
Arq. gastroenterol ; 44(2): 128-132, abr.-jun. 2007. graf, tab
Article in English | LILACS | ID: lil-465712

ABSTRACT

BACKGROUND: Infections after liver transplantations are the most important cause of morbi-mortality. In this study, we assessed the main characteristics of these infections in a southern Brazilian university hospital. METHODS: We conducted a retrospective cohort with 55 patients who underwent orthotopic liver transplantation between 1996 and 2000 in the "Hospital de Clínicas de Porto Alegre", Porto Alegre, RS, Brazil, to characterize the infections that occurred in the group. RESULTS: One or more infections (average 2.10) were diagnosed in 47 patients, especially during the first month after transplantation. The most common were bacteremia, intra-abdominal infections and pneumonia, predominantly with bacteria, especially Staphylococcus sp (and particularly S. aureus) and E. coli. The mortality rate attributed to infections was high: 17 cases of all deaths (total 27 deaths). Significant risk factors for infections included reoperation, diabetes, biliary stenosis and higher Child-Pugh scores. CONCLUSION: Infections remain a severe threat in liver transplant patients, and special efforts should be made to prevent and manage them correctly.


RACIONAL: Infecções são a causa principal de morbimortalidade em pacientes submetidos a transplantes hepáticos. OBJETIVO: Avaliar as principais características destas infecções em pacientes de um hospital universitário do sul do Brasil. MÉTODO: Uma coorte retrospectiva foi conduzida com os 55 pacientes transplantados hepáticos adultos cuja cirurgia foi realizada entre 1996 e 2000 no Hospital de Clínicas de Porto Alegre, RS, todos aos eventos infecciosos que ocorreram nesta população foram registrados. RESULTADOS: Uma ou mais infecções (média 2,1 episódios) foram diagnosticadas em 47 pacientes, o período de maior ocorrência destas foi o primeiro mês após a cirurgia. As infecções mais comuns foram: bacteremias, infecções intra-abdominais e pneumonias, a etiologia mais freqüente foi bacteriana, sendo os germes mais comuns os estafilicocos (em particular o S. aureus) e a E. coli. A taxa de mortalidade associada a infecções foi elevada: 17 óbitos de todos observados na coorte (27 no total). Os fatores de risco para infecção estatisticamente significantes foram: reoperação, diabetes, estenose de via biliar e classificação de Child-Pugh elevada. CONCLUSÃO: As infecções continuam sendo grave ameaça aos pacientes transplantados hepáticos e intenso esforço, que envolve o conhecimento da epidemiologia microbiológica, pesquisa e acompanhamento dos pacientes deve ser empregado, para prevenir e tratar de forma adequada estas complicações.


Subject(s)
Adolescent , Adult , Aged , Female , Humans , Male , Middle Aged , Liver Transplantation/adverse effects , Opportunistic Infections/mortality , Brazil/epidemiology , Epidemiologic Methods , Hospitals, University/statistics & numerical data , Immunocompromised Host , Liver Transplantation/mortality
7.
Int J Antimicrob Agents ; 27(4): 300-2, 2006 Apr.
Article in English | MEDLINE | ID: mdl-16527459

ABSTRACT

We report the first linezolid-resistant Staphylococcus aureus strain isolated in Brazil. The strain was isolated from a 10-year-old female patient with cystic fibrosis (CF) who received repeated and prolonged courses of low-dose linezolid. The strain belonged to the Brazilian endemic methicillin-resistant S. aureus clone, and the G2576U mutation was identified in domain V of the 23S rRNA. Detection of this mechanism of resistance in a CF patient is very worrisome, as these patients may become a reservoir for further dissemination of resistant strains. Our findings emphasise the importance of optimal dosage of linezolid to prevent the emergence of resistance.


Subject(s)
Acetamides/pharmacology , Cystic Fibrosis/complications , Drug Resistance, Bacterial/genetics , Oxazolidinones/pharmacology , Staphylococcal Infections/microbiology , Staphylococcus aureus/drug effects , Acetamides/administration & dosage , Acetamides/therapeutic use , Anti-Bacterial Agents/administration & dosage , Anti-Bacterial Agents/pharmacology , Anti-Bacterial Agents/therapeutic use , Brazil , Child , Female , Humans , Linezolid , Methicillin Resistance , Oxazolidinones/administration & dosage , Oxazolidinones/therapeutic use , Point Mutation , RNA, Ribosomal, 23S/genetics , Staphylococcal Infections/drug therapy , Staphylococcus aureus/isolation & purification
9.
Braz J Infect Dis ; 9(3): 191-200, 2005 Jun.
Article in English | MEDLINE | ID: mdl-16224625

ABSTRACT

UNLABELLED: Linezolid, an oxazolidinone-class antimicrobial agent, is a new drug; its use has frequently been questioned due to its high price. However, recent trials have demonstrated that the use of linezolid in mechanical ventilation-associated nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus (VAP-MRSA) may be justified due to its improved efficacy compared to vancomycin. Price and cost have different magnitudes, and clinical efficacy should always be considered in the decision-making process. Our objective was to determine whether linezolid treatment was more cost-effective than vancomycin for treating VAP-MRSA. METHODOLOGY: Elaboration of an economic model from a metanalysis of previous clinical trials comparing both drugs, through a cost-effectiveness analysis. Costs of the treatments were calculated using Brazilian parameters and were compared to the results obtained in the metanalysis. In order to compare the results with real life conditions, costs were calculated for both name brand and for generic vancomycin. RESULTS: The cost (May/2004) per unit (vial, ampoule or bag) was R$ 47.73 for the name-brand vancomycin, R$ 14.45 for generic vancomycin and R$ 214.04 for linezolid. Linezolid's efficacy in VAP-MRSA according to the metanalysis was 62.2% and vancomycin's efficacy was 21.2%. The total cost per cured patient was R$ 13,231.65 for the name-brand vancomycin, R$ 11,277.59 for generic vancomycin and R$ 7,764.72 for linezolid. CONCLUSION: Despite the higher price per unit, linezolid was more cost-effective than vancomycin.


Subject(s)
Acetamides/therapeutic use , Anti-Bacterial Agents/therapeutic use , Cross Infection/drug therapy , Oxazolidinones/therapeutic use , Pneumonia, Staphylococcal/drug therapy , Vancomycin/therapeutic use , Acetamides/economics , Anti-Bacterial Agents/economics , Cost-Benefit Analysis , Cross Infection/economics , Cross Infection/etiology , Drug Costs , Humans , Linezolid , Methicillin Resistance/drug effects , Oxazolidinones/economics , Pneumonia, Staphylococcal/microbiology , Respiration, Artificial/adverse effects , Staphylococcus aureus/drug effects , Vancomycin/economics
10.
Braz. j. infect. dis ; 9(3): 191-200, Jun. 2005. ilus, tab
Article in English | LILACS | ID: lil-412876

ABSTRACT

Linezolid, an oxazolidinone-class antimicrobial agent, is a new drug; its use has frequently been questioned due to its high price. However, recent trials have demonstrated that the use of linezolid in mechanical ventilation-associated nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus (VAP-MRSA) may be justified due to its improved efficacy compared to vancomycin. Price and cost have different magnitudes, and clinical efficacy should always be considered in the decision-making process. Our objective was to determine whether linezolid treatment was more cost-effective than vancomycin for treating VAP-MRSA. METHODOLOGY: Elaboration of an economic model from a metanalysis of previous clinical trials comparing both drugs, through a cost-effectiveness analysis. Costs of the treatments were calculated using Brazilian parameters and were compared to the results obtained in the metanalysis. In order to compare the results with real life conditions, costs were calculated for both name brand and for generic vancomycin. RESULTS: The cost (May/2004) per unit (vial, ampoule or bag) was R$ 47.73 for the name-brand vancomycin, R$ 14.45 for generic vancomycin and R$ 214.04 for linezolid. Linezolid's efficacy in VAP-MRSA according to the metanalysis was 62.2 percent and vancomycin's efficacy was 21.2 percent. The total cost per cured patient was R$ 13,231.65 for the name-brand vancomycin, R$ 11,277.59 for generic vancomycin and R$ 7,764.72 for linezolid. CONCLUSION: Despite the higher price per unit, linezolid was more cost-effective than vancomycin.


Subject(s)
Humans , Acetamides/therapeutic use , Anti-Bacterial Agents/therapeutic use , Cross Infection/drug therapy , Oxazolidinones/therapeutic use , Pneumonia, Staphylococcal/drug therapy , Vancomycin/therapeutic use , Acetamides/economics , Anti-Bacterial Agents/economics , Cost-Benefit Analysis , Cross Infection/economics , Cross Infection/etiology , Drug Costs , Methicillin Resistance/drug effects , Oxazolidinones/economics , Pneumonia, Staphylococcal/economics , Pneumonia, Staphylococcal/etiology , Respiration, Artificial/adverse effects , Staphylococcus aureus , Vancomycin/economics
11.
J Pediatr Hematol Oncol ; 27(4): 232-3, 2005 Apr.
Article in English | MEDLINE | ID: mdl-15838399

ABSTRACT

Rhodotorula sp. are commensal yeasts that may cause opportunistic infections. There have been only a few case reports of Rhodotorula fungemia in children with cancer, and in all of them the patients had a central venous catheter inserted. The authors report three nonfatal cases of fungemia by Rhodotorula in patients with post-chemotherapy neutropenia. Two of three patients required catheter removal, and a response was achieved with systemic antifungal therapy. Aggressive therapy may be required for selected high-risk patients.


Subject(s)
Antifungal Agents/therapeutic use , Fungemia/etiology , Rhodotorula/isolation & purification , Adolescent , Antineoplastic Agents/therapeutic use , Catheterization, Central Venous/adverse effects , Catheters, Indwelling/microbiology , Child , Female , Fungemia/drug therapy , Humans , Leukemia, Promyelocytic, Acute/complications , Leukemia, Promyelocytic, Acute/drug therapy , Leukemia, Promyelocytic, Acute/microbiology , Lymphoma, T-Cell/complications , Lymphoma, T-Cell/drug therapy , Lymphoma, T-Cell/microbiology , Sarcoma, Ewing/complications , Sarcoma, Ewing/drug therapy , Sarcoma, Ewing/microbiology
12.
Pediatr Blood Cancer ; 43(2): 159-63, 2004 Aug.
Article in English | MEDLINE | ID: mdl-15236284

ABSTRACT

Infective endocarditis (IE) is rare in children but is associated with substantial morbidity/mortality. Medical records of 161 new patients admitted to the Pediatric Oncology Unit in a 2 years period were reviewed to identify patients with a diagnosis of IE following the Duke criteria. Nine patients developed IE; their ages ranged from 2.4 to 11.3 years. The patients received treatment according to the results of blood cultures. TIPs are associated with a high rate of IE. The diagnosis of IE should be considered in children with cancer who have major/minor criteria as defined by the Duke criteria.


Subject(s)
Endocarditis/epidemiology , Neoplasms/complications , Brazil/epidemiology , Child , Child, Preschool , Endocarditis/diagnosis , Endocarditis/drug therapy , Female , Humans , Immunocompromised Host , Male , Neoplasms/therapy , Risk Factors
14.
Int J Infect Dis ; 8(3): 155-62, 2004 May.
Article in English | MEDLINE | ID: mdl-15109590

ABSTRACT

INTRODUCTION: Adjuvant antibiotic therapy for acute abdominal conditions is widely used. Its timing, duration, dose and spectrum, however, are not homogeneous amongst surgeons and prolonged courses are often used despite the unproven benefits of this practice. OBJECTIVE: To evaluate use and compare duration of antibiotic treatments in acute abdominal surgery. METHODS: Retrospective cohort study. The medical records of 290 patients who underwent operations for acute abdomen from July 1998 to July 1999 in a teaching hospital were reviewed. The pattern of antibiotic use and rates of postoperative complications were evaluated, along with surgical diagnosis, degree of contamination/infection, and incidence of postoperative complications. The patients were stratified according to the degree of contamination/infection noted during the operation. The study population was divided in two groups according to the duration of antibiotic use (cut-off point at the median antibiotic use in days, for each group of contamination/infection degree), and outcomes were compared. RESULTS: The degree of contamination/infection was significantly associated with an increased risk of wound infection, intra-abdominal abscess, postoperative infective complications and overall postoperative complications (p < 0.001). A long course of antibiotics was not associated with lower infective complication rates. CONCLUSIONS: Shorter courses of antibiotic therapy based on the degree of contamination/infection seem to be safe. A prospective study should confirm this hypothesis.


Subject(s)
Abdomen, Acute/surgery , Anti-Bacterial Agents/administration & dosage , Anti-Bacterial Agents/therapeutic use , Bacterial Infections/prevention & control , Postoperative Complications , Adult , Aged , Antibiotic Prophylaxis , Appendicitis , Female , Humans , Male , Middle Aged , Surgical Wound Infection/prevention & control
15.
Braz J Infect Dis ; 7(3): 224-8, 2003 Jun.
Article in English | MEDLINE | ID: mdl-14499046

ABSTRACT

We describe a case of clinical failure of vancomycin treatment of Staphylococcus aureus infection and the laboratory characteristics of the organism in a tertiary referral university hospital in southern Brazil. An 11-month-old male patient presented with pneumonia and S. aureus was isolated from his respiratory tract. Initial treatment with oxacillin and gentamicin was ineffective. Vancomycin was added to the regimen as the patient worsened, but after the 30(th) day of vancomycin treatment S. aureus was isolated from the blood. This isolate had a minimum inhibitory concentration (MIC) for vancomycin of 4 mg/mL. After pre-incubation with vancomycin the isolate displayed an increase in the expression of vancomycin resistance and colonies grew in the presence of up to 12 mg/mL vancomycin. Based on these results, and considering that the patient had not responded to vancomycin, the isolate was considered to be S. aureus heteroresistant to vancomycin (SAHV). The SAHV proved to be similar, based on DNA macrorestriction analysis, to methicillin resistant S. aureus (MRSA) isolates from other patients in the hospital who had responded to vancomycin treatment. Our findings underline the need to improve methods in the clinical laboratory to detect the emergence of S. aureus clinically resistant to vancomycin. The fact that the isolate emerged in the blood 30 days after vancomycin treatment was initiated suggests that the organism was originally an MRSA that had acquired the ability to circumvent the mechanism of action of vancomycin.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Pneumonia, Staphylococcal/drug therapy , Staphylococcus aureus/drug effects , Vancomycin Resistance , Vancomycin/therapeutic use , Fatal Outcome , Humans , Infant , Male , Microbial Sensitivity Tests , Pneumonia, Staphylococcal/microbiology , Staphylococcus aureus/isolation & purification , Treatment Failure
16.
Braz. j. infect. dis ; 7(3): 224-228, Jun. 2003. ilus
Article in English | LILACS | ID: lil-351495

ABSTRACT

We describe a case of clinical failure of vancomycin treatment of Staphylococcus aureus infection and the laboratory characteristics of the organism in a tertiary referral university hospital in southern Brazil. An 11-month-old male patient presented with pneumonia and S. aureus was isolated from his respiratory tract. Initial treatment with oxacillin and gentamicin was ineffective. Vancomycin was added to the regimen as the patient worsened, but after the 30th day of vancomycin treatment S. aureus was isolated from the blood. This isolate had a minimum inhibitory concentration (MIC) for vancomycin of 4 æg/mL. After pre-incubation with vancomycin the isolate displayed an increase in the expression of vancomycin resistance and colonies grew in the presence of up to 12 æg/mL vancomycin. Based on these results, and considering that the patient had not responded to vancomycin, the isolate was considered to be S. aureus heteroresistant to vancomycin (SAHV). The SAHV proved to be similar, based on DNA macrorestriction analysis, to methicillin resistant S. aureus (MRSA) isolates from other patients in the hospital who had responded to vancomycin treatment. Our findings underline the need to improve methods in the clinical laboratory to detect the emergence of S. aureus clinically resistant to vancomycin . The fact that the isolate emerged in the blood 30 days after vancomycin treatment was initiated suggests that the organism was originally an MRSA that had acquired the ability to circumvent the mechanism of action of vancomycin


Subject(s)
Humans , Infant , Male , Anti-Bacterial Agents , Pneumonia, Staphylococcal , Staphylococcus aureus , Vancomycin , Vancomycin Resistance , Fatal Outcome , Microbial Sensitivity Tests , Treatment Failure
18.
São Paulo; Artmed Editora; 3 ed; 2001. 428 p. tab.
Monography in Portuguese | Sec. Munic. Saúde SP, AHM-Acervo, TATUAPE-Acervo | ID: sms-2271
19.
Braz. j. infect. dis ; 3(5): 180-3, Oct. 1999.
Article in English | LILACS | ID: lil-254762

ABSTRACT

It i an accepted fact that, in many countries, pharmacies are the predominat source of medical advice over-the-counter drugs, and supplies of "prescription-only" drugs for sale without a prescription. To assess the activities conducted by pharmacists or pharmacy counter assistants in response to a common health problem, a cross-sectional study was done at 114 pharmacies in Porto Alegre, Brazil. A fictitious case-history of cough was used by trained personnel entering the pharmacy and the subsequent activities by the pharmacist or pharmacy counter assistant were analyzed. Some kind of medication was provided in 101 (88.5 percent)of the pharmacies. Pharmacists gave medication in 80 percent of pharmacies, and pharmacy assistants in 95.5 percent (p<0.03). The class of medication most frequently dispensed was the expectorants (97 times, 92.4 percent), however, systemic antibiotics were provided in 11 pharmacies (10.5 percent). Of note, the pharmacists provided antibiotics more frequently than did pharmacy assistants (p=0.016). We conclude that pharmacy advice and symptomatic medical care (expectorants) are very common and that pharmacy assistants are more likely than pharmacists to provide medication. Of concern, when pharmacists were the drug dispensers of antibiotics which should be provided by prescription only, drugs were provided without proper diagnosis, and often incorrect dosages. This reflects a pontentially dangerous practice in need of careful evaluation, education and supervision.


Subject(s)
Anti-Bacterial Agents , Antitussive Agents/therapeutic use , Cough/drug therapy , Expectorants/therapeutic use , Nonprescription Drugs/administration & dosage , Nonprescription Drugs/adverse effects , Drug Prescriptions , Self Administration , Drug Monitoring/standards , Pharmacies/standards
SELECTION OF CITATIONS
SEARCH DETAIL
...